Alderley Analytical and Concept Life Sciences
Concept Life Sciences (“Concept”), the integrated drug discovery, development and analytical services company, and Alderley Analytical, the GLP/GCP compliant, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Under the terms of the agreement, Concept will gain access to Alderley Analytical’s significant expertise in bioanalysis, and Alderley Analytical will benefit from Concept’s deep understanding of synthetic, organic and medicinal chemistry, biology, toxicology, and analytical services. The combined offering will give clients of both companies, including biotech, pharma and agrochemicals companies, access to industry-leading assay development services for quantification of new molecules in a biological matrix, using the most sensitive instrumentation available.
Michael Fort, Executive Chairman, Concept Life Sciences, commented: “The team at Alderley Analytical has built an impressive reputation for delivery of the highest quality GLP/GCP bioanalytical services. Combining this offering with our Group’s expertise, including the recent additions of translational biology and large molecule research, brings benefits to the widest group of life sciences clients.”
Liz Thomas, CEO, Alderley Analytical, said: “We are delighted to be partnering with Concept Life Sciences group at this stage in our company’s development. Concept’s size, business development network and complementary scientific capability will make the enhanced service offering highly attractive and beneficial to a wide group of national and international clients.’’